ATE314475T1 - Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität - Google Patents

Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität

Info

Publication number
ATE314475T1
ATE314475T1 AT93915414T AT93915414T ATE314475T1 AT E314475 T1 ATE314475 T1 AT E314475T1 AT 93915414 T AT93915414 T AT 93915414T AT 93915414 T AT93915414 T AT 93915414T AT E314475 T1 ATE314475 T1 AT E314475T1
Authority
AT
Austria
Prior art keywords
pseudomonas exotoxin
enhanced activity
recombinant pseudomonas
relates
domain
Prior art date
Application number
AT93915414T
Other languages
English (en)
Inventor
Ira H Pastan
David J Fitzgerald
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE314475T1 publication Critical patent/ATE314475T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93915414T 1992-06-18 1993-06-17 Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität ATE314475T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90170992A 1992-06-18 1992-06-18
PCT/US1993/005858 WO1993025690A1 (en) 1992-06-18 1993-06-17 Recombinant pseudomonas exotoxin with increased activity

Publications (1)

Publication Number Publication Date
ATE314475T1 true ATE314475T1 (de) 2006-01-15

Family

ID=25414676

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915414T ATE314475T1 (de) 1992-06-18 1993-06-17 Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität

Country Status (8)

Country Link
US (3) US5602095A (de)
EP (1) EP0646175B1 (de)
JP (1) JP3553933B2 (de)
AT (1) ATE314475T1 (de)
AU (1) AU675440B2 (de)
CA (1) CA2136724A1 (de)
DE (1) DE69333951D1 (de)
WO (1) WO1993025690A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
US6426075B1 (en) 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
DK1000163T3 (da) * 1997-07-11 2006-02-06 Us Gov Health & Human Serv Pseudomonas-exotoksin A-lignende kimære immunogener
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US6699672B1 (en) 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US7045305B1 (en) 1998-04-08 2006-05-16 The Regents Of The University Of California Methods and reagents for targeting organic compounds to selected cellular locations
AU3487499A (en) * 1998-04-08 1999-10-25 Regents Of The University Of California, The Methods and reagents for targeting organic compounds to selected cellular locations
US6277824B1 (en) * 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
WO2000052178A1 (en) * 1999-03-01 2000-09-08 Insight Strategy & Marketing Ltd. Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
DE60137969D1 (de) * 2000-12-21 2009-04-23 Us Gov Health & Human Serv Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
US20040018203A1 (en) * 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
ES2342929T3 (es) 2001-09-26 2010-07-19 The Government of the United States of America as represented by the Secretary of Health and Human Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22.
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
US6908453B2 (en) * 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
EP2829283B1 (de) 2003-04-30 2017-06-07 Universität Zürich Verfahren zur Behandlung von Krebs unter Verwendung eines Immuntoxins
US8206950B2 (en) * 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
WO2004108065A2 (en) * 2003-06-09 2004-12-16 Insight Biopharmaceuticals Ltd. Heparanase activity neutralizing anti- heparanase monoclonal antibody and other anti-heparanase antibodies
US7595054B2 (en) * 2003-06-09 2009-09-29 Healthbanks Biotech Co., Ltd. Fusion antigen used as vaccine
US7335361B2 (en) * 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
JP4813364B2 (ja) 2003-11-25 2011-11-09 アメリカ合衆国 突然変異型抗ｃｄ２２抗体および免疫複合体
US7999077B2 (en) * 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
US7611714B2 (en) 2004-10-04 2009-11-03 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
US20090155297A1 (en) * 2004-10-04 2009-06-18 Trinity Biosystems, Inc. Methods and Compositions for Inducing an Immune Response Against Multiple Antigens
EP1804832A4 (de) * 2004-10-04 2008-12-24 Trinity Biosystems Inc Verfahren und zusammensetzungen zur nadellosen abgabe von makromolekülen
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
CA2941466C (en) * 2005-07-29 2019-12-03 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Mutated pseudomonas exotoxins with reduced antigenicity
WO2007067597A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
CA2631952A1 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
EP2010205A2 (de) 2006-03-16 2009-01-07 Trinity Biosystems, Inc. Verfahren zur erhöhung der grösse von tieren mit nadellos abgegebenen konstrukten
EP2046375B1 (de) 2006-07-20 2017-04-05 The General Hospital Corporation Verfahren und zusammensetzungen zur selektiven aktivierung von protoxinen durch kombinatorisches targeting
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
US8597655B2 (en) 2007-05-10 2013-12-03 Ramot At Tel-Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
US8043621B2 (en) * 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
EP2178559B1 (de) * 2007-07-20 2015-06-24 The General Hospital Corporation Rekombinante vibrio-cholerae-exotoxine
WO2009032954A1 (en) 2007-09-04 2009-03-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
CN101983070B (zh) * 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
EP2379720B1 (de) 2009-01-20 2016-08-17 Alona Zilberberg Durch den promoter mir-21 angetriebene gezielte krebstherapie
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
CN102655882B (zh) 2009-09-11 2014-11-19 美国政府健康及人类服务部 具有降低的免疫原性的改进的假单胞菌外毒素a
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
EP3135692B8 (de) 2010-06-16 2019-03-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Antikörper zu endoplasmin und deren verwendung
PL3434346T3 (pl) 2010-07-30 2021-04-06 Medimmune, Llc Oczyszczone aktywne polipeptydy lub immunokoniugaty
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP2616045B1 (de) 2010-09-15 2017-10-25 Randall J. Mrsny Systeme und verfahren zur abgabe bioaktiver mittel unter verwendung von aus bakteriellem toxin gewonnenen transportsequenzen
US8771687B2 (en) 2010-12-02 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for treating a tumor using an antibody that specifically binds GRP94
EP2699603B1 (de) 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Für glypican-3 spezifische humane monoklonale antikörper und ihre verwendung
PE20141454A1 (es) 2011-05-06 2014-10-23 Us Gov Health & Human Serv Inmunotoxina recombinante dirigida a la mesotelina
AU2012268013B2 (en) 2011-06-09 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
WO2013040141A1 (en) 2011-09-16 2013-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with less immunogenic b cell epitopes
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
EP2764025B1 (de) 2011-10-04 2017-11-29 IGEM Therapeutics Limited Ige-antikörper gegen hmw-maa
SG11201407972RA (en) 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014031476A1 (en) 2012-08-21 2014-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
US9416190B2 (en) 2012-09-27 2016-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014100443A2 (en) 2012-12-20 2014-06-26 Medimmune, Llc Methods of producing immunoconjugates
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CA2926215A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
ES2764833T3 (es) 2013-10-11 2020-06-04 The United States Of America Represented By The Sec Dep Of Health And Human Services Anticuerpos contra TEM8 y su uso
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
WO2015120058A2 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
MA39776A (fr) 2014-03-24 2017-02-01 Hoffmann La Roche Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
AU2015255834B2 (en) 2014-05-07 2020-05-21 Applied Molecular Transport Llc Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN106999578B (zh) 2014-07-31 2022-03-04 美国政府(由卫生和人类服务部的部长所代表) 针对epha4的人类单克隆抗体和其用途
JP6613304B2 (ja) 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗ｃｄ２７６抗体（ｂ７ｈ３）
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
WO2017077367A1 (en) 2015-11-06 2017-05-11 Uniwersytet Warszawski Purification method for recombinant exotoxin a, recombinant exotoxin a muteins and recombinant proteins comprising exotoxin a fragments
EP3374396A1 (de) 2015-11-13 2018-09-19 The United States of America, as represented by the secretary, Department of Health and Human Services Anti-bcma-polypeptide und proteine
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
EP3518968B1 (de) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1-env-fusionspeptid-immunogene und deren verwendung
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018119279A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
WO2018176031A1 (en) 2017-03-24 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
US11390683B2 (en) 2017-05-18 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
CA3059472A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
US11795235B2 (en) 2017-09-18 2023-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxins with albumin binding domain
US11136356B2 (en) 2017-10-16 2021-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
CN112105376A (zh) 2018-03-08 2020-12-18 应用分子运输公司 用于经口递送的毒素衍生的递送构建体
AU2019301675A1 (en) 2018-07-12 2021-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
CA3106544A1 (en) 2018-08-08 2020-02-13 Mitchell Ho High affinity monoclonal antibodies targeting glypican-2 and uses thereof
US20210353740A1 (en) 2018-09-23 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
WO2020086483A1 (en) 2018-10-22 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant gp120 protein with v1-loop deletion
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
US20220064324A1 (en) 2019-01-08 2022-03-03 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting mesothelin for treating solid tumors
CN113784987A (zh) 2019-01-22 2021-12-10 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
WO2021003297A1 (en) 2019-07-02 2021-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind egfrviii and their use
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina
CN114729041A (zh) 2019-10-22 2022-07-08 美国政府(由卫生和人类服务部的部长所代表) 用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
WO2021097289A1 (en) 2019-11-15 2021-05-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pegylated recombinant immunotoxins
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
US20240075158A1 (en) 2020-12-22 2024-03-07 Jiangsu Hengrui Pharmaceutical Co., Ltd. Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
CN117500831A (zh) 2021-06-09 2024-02-02 美国政府(由卫生和人类服务部的部长所代表) 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
AU2022416639A1 (en) 2021-12-17 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024104584A1 (en) 2022-11-17 2024-05-23 University Of Cape Town Deimmunized pseudomonas exotoxin a

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity

Also Published As

Publication number Publication date
DE69333951D1 (de) 2006-02-02
US5854044A (en) 1998-12-29
WO1993025690A1 (en) 1993-12-23
AU4540493A (en) 1994-01-04
JP3553933B2 (ja) 2004-08-11
US5602095A (en) 1997-02-11
EP0646175A1 (de) 1995-04-05
CA2136724A1 (en) 1993-12-23
US5821238A (en) 1998-10-13
EP0646175B1 (de) 2005-12-28
AU675440B2 (en) 1997-02-06
JPH07508641A (ja) 1995-09-28

Similar Documents

Publication Publication Date Title
ATE314475T1 (de) Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
MX9306960A (es) Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion.
NZ238812A (en) Protein comprising enzyme-like binding protein and variable fused polypeptide coupled by interconnecting peptide
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
IL105724A (en) PURIFIED FORMS OF DNase
ATE190659T1 (de) Rekombinante immuntoxine
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
ATE438658T1 (de) Neue polypeptide aus bienengift und dessen gebrauchsverfahren
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
DE69125381D1 (de) Proteinstruktur des pflanzlichen toxins gelonin
YU49138B (sh) Proteinski derivat humane lipaze stimulisane žučnom soli
DK1431391T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
TR199802504T2 (xx) N�rotoksik yaralanmalar�n tedavisi i�in bukminsterflirin kullan�lmas�.
ATE286405T1 (de) Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers
ATE222498T1 (de) Putamen ovi
TR200003552T2 (tr) İnsan proteini C polipeptit.
ATE310083T1 (de) Deprenyl induziertes protein
RU95118989A (ru) Штамм метилотрофных бактерий pseudomonas sp. впкм n b-6798, способный использовать формальдегид в качестве единственного источника углерода и энергии в бедной минеральной среде
IE950321L (en) Recombinant pseudomonas exotoxin: construction of an active¹immunotoxin with low side effects
ATE249229T1 (de) Verwendung von putamen ovi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties